2002-2007年世界上市新药合成综述

MINIREVIEWSINMEDICINALCHEMISTRY,2004,4,20723320713895575/044500002004BENTHAMSCIENCEPUBLISHERSLTDSYNTHETICAPPROACHESTOTHE2002NEWDRUGSJINLIANDKEVINKCLIUPFIZERGLOBALRESEARCHANDDEVELOPMENT,PFIZERINC,GROTONCT06340,USAABSTRACTNEWDRUGSAREINTRODUCEDTOTHEMARKETEVERYYEARANDEACHINDIVIDUALDRUGREPRESENTSAPRIVILEGEDSTRUCTUREFORITSBIOLOGICALTARGETINADDITION,THESENEWCHEMICALENTITIESNCESNOTONLYPROVIDEINSIGHTSINTOMOLECULARRECOGNITION,BUTALSOSERVEASDRUGLIKELEADSFORDESIGNINGFUTURENEWDRUGSTHEREFORE,ITISIMPORTANTTOBEACQUAINTEDWITHTHESENEWSTRUCTURESASWELLASTHEIRSYNTHESESTOTHESEENDS,THISREVIEWCOVERSTHESYNTHESESOF28NCESMARKETEDIN2002KEYWORDSSYNTHESIS,NEWDRUG,NEWCHEMICALENTITIES,MEDICINE,THERAPEUTICAGENTSINTRODUCTIONDOZENSOFNEWDRUGSAREREGISTEREDANDLAUNCHEDEVERYYEARAROUNDTHEWORLDALTHOUGHTHOUSANDSOFDRUGSHAVEBEENMARKETEDHISTORICALLY,THESTRUCTURESIMILARITYAMONGSOMEDRUGSISOBVIOUSANDEVENMORESOFORDRUGSTARGETINGINTHESAMEGENEFAMILYFURTHERMORE,ITHASBEENDEMONSTRATEDTHATMOLECULESWHICHSHARETHESAMEORSIMILARCHEMICALTEMPLATECANBEFURTHERMODIFIEDFORDIFFERENTTHERAPEUTICINDICATIONSAGAINSTTHESIMILARGENEFAMILYTHEREFORE,MEDICINALCHEMISTS,BEINGAWAREOFTHESENEWDRUGSTRUCTURES,CANSTRIKEANDADOPTIDEASFORTHEIROWNINNOVATIONSINADDITION,PREPARATIONOFTHESEDRUGMOLECULESHASBEENSTUDIEDEXTENSIVELYTOMAKEITCONCISEDUETOTHECOSTOFGOODSCONSIDERATIONANDTOENSUREENVIRONMENTFRIENDLINESSHAVINGSUCHROBUSTANDRELIABLESYNTHETICMETHODSINHANDTOACCESSTHESECORESTRUCTURESWILLSTEERSYNTHETICEFFORTSMOREEFFECTIVELYTOWARDTHEMOSTPROMISINGCOMPOUNDSANDHELPFOCUSTHEOPTIMIZATIONTOWARDOTHERCHALLENGINGPROPERTIESSUCHASADMEIN2002ALONE,33NCESINCLUDINGBIOLOGICALDRUGS,ANDTWODIAGNOSTICAGENTSREACHEDTHEMARKET15THISREVIEWARTICLEWILLFOCUSONTHESYNTHESESOFTHE28NEWDRUGSMARKETEDLASTYEARFIGURE1,BUTEXCLUDESNEWINDICATIONSFORKNOWNDRUGS,NEWCOMBINATIONSANDNEWFORMULATIONSTHESYNTHESESOFTHESENEWDRUGSWEREPUBLISHEDSPORADICALLYINDIFFERENTJOURNALSANDPATENTSITISOURINTENTIONTOCOMPILETHESYNTHESESOFNEWDRUGSYEARLYINTOANANNUALREVIEWFORTHEREADERSADVANTAGETHESYNTHETICROUTESCITEDHEREREPRESENTTHEMOSTSCALABLEMETHODSACCORDINGTOTHEBESTOFTHEAUTHORSKNOWLEDGEANDAPPEARINALPHABETICALORDERBYGENERICNAMEADEFOVIRDIPIVOXILHEPSERATMADEFOVIRDIPIVOXIL1,DISCOVEREDBYGILEAD,BECAMETHEFIRSTNUCLEOSIDEANALOGUETOGAINFDAAPPROVALFORTHETREATMENTOFCHRONICHEPATITISBINFECTION6ADEFOVIRWORKSBYBLOCKINGVIRALREPLICATION6THESYNTHESIS7,8OFADEFOVIRDIPIVOXIL1INVOLVESAFOURSTEPPROCESS9,10ASDEPICTEDINSCHEME1ADENINE29WASCONDENSEDWITHETHYLENECARBONATE30INHOTDMFTOAFFORDINTERMEDIATE9ADDRESSCORRESPONDENCETOTHESEAUTHORSATTHEPFIZER,GROTON,CT06340,USATEMAILJIN_LIGROTONPFIZERCOMKEVIN_K_LIUGROTONPFIZERCOM2HYDROXYETHYLADENINE31IN8395YIELDALKYLATIONOF31WASCARRIEDOUTUSINGDIETHYLPTOLUENESULFONYLOXYMETHANEPHOSPHONATE32ANDSODIUMTBUTOXIDEINDMFPHOSPHONATEESTER33WASTHENCLEAVEDWITHBROMOTRIMETHYLSILANETOFURNISH34ANDESTERIFICATIONOFTHEPHOSPHORICACIDTOAPPENDTHEPIVALOYLOXYMETHYLGROUPPROVIDEDADEFOVIRDIPIVOXIL1AMRUBICINHYDROCHLORIDECALSEDTHISDRUGISTHEFIRSTANTHRACYCLINEANTICANCERANTIBIOTICPRODUCEDBYPURELYSYNTHETICMETHODSITWASDISCOVEREDBYSUMITOMOPHARMACEUTICALS,ANDISFORTHETREATMENTOFNONSMALLCELLLUNGCANCERANDSMALLCELLLUNGCANCER11TETRALONE35WASTREATEDWITHAMMONIUMCARBONATEANDPOTASSIUMCYANIDESTRECKERREACTIONTOGIVETHECORRESPONDINGAMINONITRILEINTERMEDIATE,WHICHWASHYDROLYZEDUNDERBASICCONDITIONSTOAFFORDAMINOACID36INEXCELLENTYIELD12THECARBOXYLICACIDIN36WASESTERIFIEDWITHHCLINMETHANOLTOTHECORRESPONDINGMETHYLESTER,WHICHWASTREATEDWITHDMANDELICACIDINTOLUENETOGIVEOPTICALLYPURELEVOROTATORYESTER37IN33YIELDSODIUMMETHYLSULFINYLMETHIDETREATMENTOF37FOLLOWEDBYREDUCTIONWITHZINCYIELDEDAMINOKETONE38,WHICHWASACYLATEDTOGIVEAMIDOKETONE39IN81YIELDFROM37COMPOUND39WASCONVERTEDTOTETRACYCLICAMIDOKETONE40INONESTEP90YIELDBYHEATINGWITHPHTHALICANHYDRIDEINTHEPRESENCEOFALCL3NACLAT170CKETONE40WASPROTECTEDASITSKETAL41INORDERTOPROVIDEFORSUBSEQUENTREGIOSPECIFICBROMINATIONTREATMENTOF41WITH1,3DIBROMO5,5DIMETHYLHYDANTOINDDHUNDERILLUMINATIONINREFLUXINGBENZENEFORMEDOXAZINE42IN89YIELDHYDROLYSISOFTHEOXAZINERINGANDDEKETALIZATIONWERESIMULTANEOUSLYAFFECTEDBYHEATING42WITH3NSULFURICACIDTOGIVECISAMINOALCOHOL43IN82YIELDMODIFIEDARCAMONECONDITIONSAGOSO2CF3INETHER/TETRAMETHYLUREA/DCMWEREEMPLOYEDFORTHESTEREOSELECTIVEGLYCOSIDATIONOF43WITH2DEOXY3,4DIOACETYLDERYTHROPENTOPYRANOSYLBROMIDE4413TOGIVETHEPROTECTEDGLYCOSIDEIN86YIELDBASICHYDROLYSISOFTHEPROTECTEDCOUPLINGPRODUCTFOLLOWEDBYHCLSALTFORMATIONGAVEAMRUBICINHYDROCHLORIDE2IN90YIELDARIPIPRAZOLEABILIFYTMTHISATYPICALANTIPSYCHOTICAGENTWASORIGINALLYDISCOVEREDBYOTSUKAANDWASCODEVELOPEDANDCOMARKETED208MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUNHOHOOHOSNHNHOOONAHONNCFCO2HCO2HOOOHOOSOOONSOOOOHOOOOHOOHOOSOOONSOHOOOSOOOOOOOHOHHOOOSOOONSOHOOOHOSOOONANANANANANANANANANAHOHOHHHSOFFFFFFNHCLNNOMEONONOOHFOHFNNNNNH2OPOOOOOOOOOOOOHHOOHOOHNH2HCLCLCLNNONHOOONHHCLNHONHFFFFFFHHHHONNSOOCLNHNH2HNO7FULVESTRANT12GEFITINIB13ADEFOVIRDIPIVOXIL1AMRUBICINHYDROCHLORIDE2ARIPIPRAZOLE3DEXMETHYLPHENIDATEHCL4DUTASTERIDE5ERTAPENEMSODIUM6ESCITALOPRAMOXALATE7ETORICOXIB8EZETIMIBE9FONDAPARINUXSODIUM10FROVATRIPTAN11SYNTHETICAPPROACHESTOTHE2002NEWDRUGSMINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2209FIG1CONTDNFOOHOOH2NCH3SO3HPAZUFLOXACINMESILATE20CLOOOOONOOOOHOOHPIMECROLIMUS21OONHHNNOOOHOOOOHOSNAOOONHNOOHHNOHNHNONOHOHOHHNHOOH2NOHOONOOOHOHOHOH2NOHPPOHOOHOOHOHOOONO2FFFNNOOOONNHNNOOHNOSOONONANOFNOHOSNOOOLANDIOLOL14MICAFUNGINSODIUM15NERIDRONATE16NITISINONE17OLMESARTANMEDOXOMIL18PARECOXIBSODIUM19PRULIFLOXACIN22O210MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUFIG1CONTDNHSOOOOHNOOONA4H2ONNOHHOOONSOOFCA2SOOONSHOBROHOHOONAONOSH2NOONNFNNNFFHOSIVELESTATSODIUMHYDRATE242ROSUVASTATINCALCIUM23TREPROSTINIL26VALDECOXIB27VORICONAZOLE28TIOTROPIUMBROMIDE25FIG1STRUCTURESOF28NEWDRUGSMARKETEDIN2002NNNHNNH2OOONNNNNH2OHNNNNNH2OPOETOETOPOETETOOTSONNNNNH2OPOHOHOTMSBRCLOONNNNNH2OPOOOONAOH,DMFCH3CN,2930120OC8395313332NAOBUT,DMF3548348090TEA,NMP4012SCHEME1SYNTHESISOFADEFOVIRDIPIVOXILBYBRISTOLMYERSSQUIBBTHECOMPOUNDISAPARTIALAGONISTATDOPAMINED2AND5HT1AANDANANTAGONISTAT5HT2ARECEPTORS14ITISINDICATEDFORTHETREATMENTOFSCHIZOPHRENIAHYDROXYLQUINOLINONE45WASALKYLATEDWITH1,4DIBROMOBUTANEINTHEPRESENCEOFPOTASSIUMCARBONATEINDMFTOGIVE46IN78YIELD15BROMIDE46WASCONDENSEDWITH12,3DICHLOROPHENYLPIPERAZINE1647INTHEPRESENCEOFNAIANDTEATOGIVEARIPIPRAZOLE3IN87YIELDDEXMETHYLPHENIDATEHYDROCHLORIDEFOCALINTMDEXMETHYLPHENIDATE4ISTHEMOREPHARMACOLOGICALLYACTIVEDTHREOENANTIOMEROFMETHYLPHENIDATEWHICHWASMARKETEDFORTHETREATMENTOFATTENTIONDEFICIT/HYPERACTIVITYDISORDERADHDIN195417INADDITION,ITHASBEENSHOWNTHATTHEREARESIGNIFICANTMETABOLICDIFFERENCESBETWEENTHETWOENANTIOMERSTHISDRUGWASDISCOVEREDBYCANGENEANDISMARKETEDBYNOVARTISTODATE,SEVERALMETHODSHAVEBEENDISCLOSEDINTHELITERATUREFORPREPARINGSYNTHETICAPPROACHESTOTHE2002NEWDRUGSMINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2211OCH3OCH3OOCH3OCH3NH2CH3OOHOHNHACCH3OOOOBROACACOOHOHNCH3OOOOOCH3OCH3OCH3NH2CO2HOHOHNH2CH3OOOOOHOOHOHOHNHACCH3OOOOOHOHNH2CH3OOOOHHCLOCH3OCH3NHACCH3OOOOOCH3OCH3CO2CH3NH2351KCN,NH42CO3,50ETOH,992BAOH2,H2O,92361HCL,MEOH,952DMANDELICACIDTOLUENE,IPA,33371NAH,DMSO,THF2ZN,NAOH/H2O,TOLUENE38AC2O,PYRIDINE,TOLUENE80FROM3739ALCL3,NACL,170OC9040ETHYLENEGLYCOLTSOH,TOLUENE,88DDH,BENZENE,HV,8942413NH2SO4,8243442HCL,MEOH,90AGOSO2CF3,ETHERTETRAMETHYLUREA,CH2CL2861KOH,CH2CL2MEOH,2SCHEME2SYNTHESISOFAMRUBICINHYDROCHLORIDETHEDTHREOENANTIOMEROFMETHYLPHENIDATE,MOSTINVOLVINGWITHENZYMATICRESOLUTION18,ORCRYSTALLIZATION/RECRYSTALLIZATIONMETHODS19,20ANASYMMETRICSYNTHESIS21ROUTEISDEPICTEDINSCHEME4RPIPECOLICACID48WASREACTEDWITHBOC2OTOAFFORDNBOCPIPECOLICACID49TREATMENTOF49WITHN,ODIMETHYLHYDROXYLAMINEINDCMPROVIDEDTHEWEINREBAMIDE50IN93YIELDREACTIONOFAMIDE50WITHPHENYLLITHIUMAT23CINET2OFURNISHEDENANTIOPUREKETONE51IN73YIELDKETONE51WASCONVERTEDTOCHIRALAROMATICALKENE52USINGMETHYLENETRIPHENYLPHOSPHORIUMYLIDEINTHFATRTTHETRANSFORMATIONOFOLEFIN52TODIASTEREOMERICALCOHOLS53AND54WASACHIEVEDUSINGBH3THFCOMPLEXIN89OVERALLYIELDDIASTEREOMERICALLYPUREALCOHOL53WASSUBJECTEDTOPDCMEDIATEDOXIDATIONINDMFFOLLOWEDBYTREATMENTWITHEXCESSETHEREALDIAZOMETHANETHERESULTINGNBOCMETHYLPHENIDATEWASDEPROTECTEDWITH3NMETHANOLICHCLTOGIVEDEXMETHYLPHENIDATE4ASAWHITESOLIDIN67YIELD212MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUNHOHOCLCLNNONHONHOBRCH24OCLCLNNH45BRCH24BR,K2CO3DMF,60OC,784647NAL,TEACH3CN,873SCHEME3SYNTHESISOFARIPIPRAZOLENHOHONBOCOHNOHOBOCNBOCNHOMEONNOBOCONBOCOHNBOCOHNOBOCBOC2O,TEAMEOH,RT,9749N,ODIMETHYLHYDROXYLAMINEBOP,TEA,DCM,RT,9350PHLI,ET2O23OC,7351METHYLTRIPHENYLPHOSPHORIUMBROMIDEKOBUT,THF,RT,93521BH3THF,THF2NAOH,H2O2,RT536454251PDC/DMF2CH2N23HCL/MEOH6744853SCHEME4SYNTHESISOFDEXMETHYLPHENIDATEDUTASTERIDEAVODARTTMTHISSTEROID5REDUCTASETYPE1AND2INHIBITORWASPATENTEDBYGLAXOSMITHKLINEITISUSEDFORTHETREATMENTOFSYMPTOMATICBENIGNPROSTATICHYPERPLASIAINMENWITHANENLARGEDPROSTATETOIMPROVEURINARYSYMPTOMS,REDUCETHERISKOFACUTEURINARYRETENTIONANDBPHRELATEDSURGERY22STEROIDALDUTASTERIDE5WASSYNTHESIZEDFROM3OXO4ANDROSTENE17CARBOXYLICACID5523OXIDATIONOF55WITHPOTASSIUMPERMANGANATE,SODIUMPERIODATEANDSODIUMCARBONATEINREFLUXINGTBUTYLALCOHOLANDWATERGAVESECOSTEROID56WHICHWASCYCLIZEDWITHAMMONIUMACETATEINACETICACIDTOGIVE4AZASTEROID57INGOODYIELDSTEREOSELECTIVEHYDROGENATIONOF57WITHH2OVERPTO2INHOTACETICACIDANDINTHEPRESENCEOFAMMONIUMACETATEYIELDEDSATURATEDAZASTEROID58,WHICHWASDEHYDROGENATEDWITHDDQINTHEPRESENCEOFBISTRIMETHYLSILYLTRIFLUOROACETAMIDEBSTFA59INREFLUXINGDIOXANETOGIVE60TREATMENTOF60WITHTHIONYLCHLORIDEGAVETHECORRESPONDINGACYLCHLORIDEINTERMEDIATE,WHICHWASTHENCONDENSEDWITH2,5BISTRIFLUOROMETHYLANILINE61BYMEANSOFDMAPINHEATEDTOLUENETOGIVEDUTASTERIDE5IN57YIELDFROMINTERMEDIATE60ERTAPENEMSODIUMINVANZTMERTAPENEMSODIUM6WASINTRODUCEDINTHEUSANDEUROPEBYMERCKFORMERLYFONDAPARINSODIUM,10ISASYNTHETICPENTASACCHARIDEHEPARINOIDFACTORXAANTAGONISTANDTHROMBOKINASEINHIBITORLAUNCHEDEXTENSIVELYBYSANOFISYNTHLABOFORMERLYSANOFIANDORGANONASATREATMENTANDPROPHYLAXISFORDEEPVEINTHROMBOSISDVTANDSYMPTOMATICPULMONARYEMBOLISMFOLLOWINGHIPORKNEESURGERYITISALSOBEINGDEVELOPEDASAPOTENTIALTREATMENTFORCORONARYARTERYDISEASES40FONDAPARINUXHASACOMPLEXSTRUCTURESTARTINGFROMDGLUCOSE,DCELLOBIOSE,ANDDGLUCOSAMINE,THEPRODUCTIONPROCESSFORTHESYNTHESISOFTHEPENTASACCHARIDEINVOLVESABOUT55STEPSTHESYNTHESISWASACCOMPLISHEDBYPREPARINGAFULLYPROTECTEDPENTASACCHARIDE,ANDTHENCONVERTINGITINTOTHEFINALPRODUCTTHECHOICEOFPROTECTINGGROUPSWASDICTATEDBYTWOFACTORSTHENEEDTOINTRODUCESULFATESUBSTITUENTSOASWELLASNLINKED,CARBOXYLATEGROUPSANDHYDROXYLGROUPS,INTHEPROPERPOSITIONSONTHETARGETMOLECULE,ANDTHECONSTRAINTSOFCURRENTMETHODSFOROLIGOSACCHARIDESYNTHESIS,PARTICULARLYTHEUSEOF2AZIDOGLUCOSEDERIVATIVESTOACHIEVESTEREOSELECTIVEINTRODUCTIONOFDLINKEDGLUCOSAMINEUNITSALLTHEMONOSACCHARIDESYNTHONSWEREOBTAINEDFROMGLUCOSEORFROMGLUCOSAMINE41,42,ANDTHESYNTHESIS4244ISOUTLINEDINSCHEME10TRISACCHARIDE108ANDDISACCHARIDE109ARETHETWOKEYBUILDINGBLOCKSINTHESYNTHESISCOUPLING108AND109WASCARRIEDOUTAT20CINDCEFULLYPROTECTEDPENTASACCHARIDE110WASTHENCONVERTEDINTOTHETARGETCOMPOUND10USINGTRADITIONALMETHODSSAPONIFICATION,OSULFATION,CLEAVAGEOFBENZYLETHERSWITHSIMULTANEOUSREDUCTIONOFAZIDOINTO216MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUNCO2MEMECHOMEO2SNNHPHMEO2SSMGCLNMEONMEOMENNCLNOME2NCLNME2SO2ME2NHCLNMENOMEMEONMENHPHPOPH2ONOME2NCLSO2MEMEO2SNONSONMEHOSO2MECO2HNNSO2MECLCO2MENME79HNMEOME,IPRMGCLTOLUENE,7OC,9580DIBALH,TOLUENE98EE265125OSCHEME11SYNTHESISOFFROVATRIPTANAOOACHHHHOOHHHSCF2CF3HBRSCF2CF3H2O2AOOACHHSCF2CF3HHOOHHHSCF2CF3OH1297130777/RATIOABOUT2511317712CRYSTALLIZATION30OVERALLFROM129771321CUBR2,LIBR,AC2O2NAOH8085MG,CUCL,34C90957OSCHEME12SYNTHESISOFFULVESTRANTDEMETHYLATEDWITHMETHIONINEINREFLUXINGMETHANESULFONICACIDTOAFFORD135IN47YIELD53COMPOUND135WASACYLATEDTOGIVEACETATE136,WHICHWASTREATEDWITHREFLUXINGTHIONYLCHLORIDETOYIELDCHLOROPYRIMIDINE137CHLORIDE137WASCONDENSEDWITH3CHLORO4FLUOROANILINE138INREFLUXINGIPATOYIELDANILINOQUINAZOLINE139IN56YIELDFROM136THEACETATEPROTECTINGGROUPINCOMPOUND139WASHYDROLYZEDWITHAMMONIUMHYDROXIDEINMETHANOL,ANDTHEFREEPHENOLWASALKYLATEDWITH34MORPHOLINYLPROPYLCHLORIDE140TOGIVEGEFITINIB13IN55YIELDSYNTHETICAPPROACHESTOTHE2002NEWDRUGSMINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2221SOCL2MEOMEOCO2HNH2HCONH2H2NFCLNNHMEOMEOONNNHACOMEOFCLNNHHOMEOONCLOAC2ONNOMEOHNFCLNONNHACOMEOONNACOMEOCL133190OC,18134METHIONINEMESO3H/100OC135PYRIDINE100OC75136DMF,90OC137138IPA,95OC56FROM13613930NH4OHMEOH,9514013SCHEME13SYNTHESISOFGEFITINIBHOOOHOOCLOOOOOOOOOOONHHNNOOOHOOOOHOH2NHNNOOOK2CO3,BR1K2CO3,KI,DMSO,100OC,30MIN100OC,15H214257143144ACETON,76145IPA,30OC,16H4314614141SCHEME14SYNTHESISOFLANDIOLOLLANDIOLOLHYDROCHLORIDEONOACTLANDIOLOLHYDROCHLORIDE14WASLAUNCHEDINJAPANBYONOFORTHETREATMENTOFINTRAOPERATIVETACHYARRHYTHMIAITIMPROVESTACHYARRHYTHMIABYSELECTIVELYBLOCKING1RECEPTORSLOCATEDMAINLYINTHEHEARTANDBYINHIBITINGTHEACTIONOFCATECHOLAMINE54THESYNTHESISOFLANDIOLOLAPPEAREDINANEARLIERPATENTIN199055ESTERIFICATIONOF34HYDROXYPHENYLPROPIONICACID141WITH2,2DIMETHYL1,3DIOXOLAN4YLMETHYLCHLORIDE142INDMSOGAVEDESIREDESTER143IN57YIELDTREATMENTOFPHENOL143WITHBROMOEPOXIDE144INTHEPRESENTOFK2CO3AFFORDEDETHER145IN76YIELDEPOXIDE145WASTHENREACTEDWITHFREEAMINE146VIAANEUCLEOPHILICRINGOPENINGPROCESSTOPROVIDELANDIOLOL14MICAFUNGINSODIUMFUNGUARG222MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUCLHONCO2MENHOH2NOHNONHOOHHOOSHOOHOONOOOHOHNNROHHOHNOOHHOHOHHOCH24CH3NNNONOOHNHOH2NOHNONHOOHHOOSHOOHOONOOOHOHNNOHHOHNOOHHOHOONOOOMEONOO147148TEA,THF8414911NNAOH,ETOH/THF,982HOBT,WSCHCL,CH2CL2,95150150,DMAPDMF,53FR901379ACYLASERCOCH214CH3151RH15SCHEME15SYNTHESISOFMICAFUNGINSODIUMH2NOHOH2NPPOHHOHOOOOHOH1PCL3,H3PO3,85OC2H2O,7816152SCHEME16SYNTHESISOFNERIDRONATETHESEMISYNTHETICECHINOCANDINANTIFUNGALAGENT,MICAFUNGINSODIUM15,ISA1,3GLUCANSYNTHASEINHIBITORDISCOVEREDBYFUJISAWAITISFORTHETREATMENTANDPREVENTIONOFINFECTIONSCAUSEDBYASPERGILLUSANDCANDIDASUCHASFUNGEMIA,RESPIRATORYMYCOSISANDGASTROINTESTINALMYCOSIS56THEKEYINTERMEDIATEFORTHESIDECHAINOFMICAFUNGIN15WASPREPAREDBYREGIOSELECTIVE1,3DIPOLARCYCLOADDITIONREACTIONOF4METHOXYCARBONYLBENZHYDROXAMICACIDCHLORIDE147AND4PENTYLOXYPHENYLACETYLENE148WITHTEAINTHF57BASICHYDROLYSISOFTHUSOBTAINEDESTER149,FOLLOWEDBYCONDENSATIONWITH1HYDROXYBENZOTRIAZOLEHOBTGAVETHECORRESPONDINGACTIVATEDESTER150IN95YIELDTHECYCLICPEPTIDECORE151,OBTAINEDBYACYLASECATALYZEDHYDROLYSISOFTHENATURALPRODUCTFR901379,WASACYLATEDWITH150TOGIVEMICAFUNGIN15IN53YIELDNERIDRONATENERIXIATHISBISPHOSPHONATECOMPOUNDWASDEVELOPED,ANDISMARKETED,BYABIOGENPHARMATHISDRUGISTHEFIRSTTREATMENTEVERFOROSTEOGENESISIMPERFECTA586AMINOHEXANOICACID152WASREACTEDWITHPHOSPHORUSTRICHLORIDEANDPHOSPHOROUSACIDAT85OC,ANDTHENWATERSYNTHETICAPPROACHESTOTHE2002NEWDRUGSMINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2223CLNO2OF3COOOFFFNO2OOMEMEOSIME3NC153154TEA,CHCL3,TMSCN,9117NITISINONEORET3N,CHCL3,89SCHEME17SYNTHESISOFNITISINONEPRNHNCO2ETOHMEMENH2CNNCH2NOOCH3CLOBRNNNNCPH3PRCOME3NNOHNNNNCPH3OOOOONNOHNNNNCPH3HOOPRNHNCNCNNNOHETOONNNNCPH3PRNHNCO2ETCO2ETNNOHNHNNNOOOOOMEMGCL1551CH3CN,2XYLENE,9615716NHCL,802HCLG,ETOH,86158ET2O,CH2CL295159160BUTOK/ACNME280161LIOH,DIOXANE/H2O162163K2CO3,ACNHME88FROM16116425ACOHAQ8118156SCHEME18SYNTHESISOFOLMESARTANMEDOXOMILWASADDEDTOGENERATEFREEDIPHOSPHONICACID16IN78OVERALLYIELD59NITISINONEORFADINTHISREVERSIBLEINHIBITOROF4HYDROXYPHENYLPYRUVATEDIOXYGENASEWASDISCOVEREDBYSWEDISHORPHANANDISCOMARKETEDBYAPOTEKETABANDRAREDISEASETHERAPEUTICSITISUSEDASANADJUNCTTODIETARYRESTRICTIONOFTYROSINEANDPHENYLALANINEINTHETREATMENTOFHEREDITARYTYROSINEMIATYPE1HT1DISEASE60NITISINONE17WASSYNTHESIZEDINONESTEPBYREACTING2NITRO4TRIFLUOROMETHYLBENZOYLCHLORIDE153WITHCYCLOHEXANE1,3DIONE154INTHEPRESENCEOFTEAANDTRIMETHYLSILYLCYANIDEOR2CYANO2TRIMETHYLSILYLOXYPROPANE61OLMESARTANMEDOXOMILBENICARTMTHISANGIOTENSINIIANTAGONISTWASDISCOVEREDBYSANKYOANDLICENSEDTOFORESTFORTHETREATMENT,ALONEORINCOMBINATIONWITHOTHERANTIHYPERTENSIVEAGENTS,OFHIGHBLOODPRESSURE62THEIMIDAZOLERINGOFOLMESARTAN18WASCONSTRUCTEDWITHDIAMINOMALEONITRILE155ANDTRIMETHYLORTHOBUTYRATE156INCH3CNTHENXYLENETOGIVE157IN96YIELD63ACIDHYDROLYSISOF157IN6NHCLGAVETHEDICARBOXYLICACIDINTERMEDIATEAFTERESTERIFICATIONOFTHEDIACIDINETHANOLINTHEPRESENCEOFHCL,DIESTER158WASTREATEDWITHMEMGCLTOGIVE41HYDROXYALKYLIMIDAZOLE159IN95YIELDALKYLATIONOF159WITHBIPHENYLBROMIDE160INTHEPRESENCEOFPOTASSIUMTBUTOXIDEAFFORDED161IN80YIELDESTER161WASTHENHYDROLYZEDTOFREECARBOXYLICACID162UNDERBASIC224MINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2LIANDLIUOONSOOH2NNOHNAONSOONOONOH165NH2OHHCL,NAOACETOH/H2O,70OC951661NHEXLI,THF,1510OC1672ETOAC,15OC5927VALDECOXIB1CLSO3H,TFA,525OC2NH4OH,1015OC652STEPS19PARECOXIBSODIUM1CH3CH2CO2O,H2SO4,80OC2NAOH,ETOH,50OC642STEPSSCHEME19SYNTHESISOFPARACOXIBSODIUMAC2OBRCH2CH2BRCO2HFFFFOFFFCO2ETHNHOCH3HNHOCO2ETFFFNCCO2ETFFFHNONOOFH2NOOHCH3SO3HCO2ETFFFBUTO2CNCCO2ETFFFH2NONOCO2ETOFHNOCH3HOCH2CO2ETFFFNHOPTSAH2OCO2ETFFFNCCO2ETFFFH2N1681ETBR,K2CO3,DMSO2NCCH2CO2BUT,K2CO3169TOLUENE,REFLUX90FROM168170PHCH2NET3CL10NNAOH171H2O2,NAOH81FROM17017213NAOCLAQ25NNAOH,961732NNAOH,971SOCL2,IMIDAZOLE,TEA2ETO2CCH2CO2KMGCL2,TEA,DMF1751ME2NCHOME2AC2O,CH2CL22S2AMINO1PROPANOLETOH174176K2CO3,DMSO100OC80FROM1741772NAOH,ETOH/H2O,9826NHCL,903CH3SO3H,ETOH,9420PAZUFLOXACINMESILATESCHEME20SYNTHESISOFPAZUFLOXACINMESILATECONDITIONS,AND162WASTREATEDWITHCHLORIDE163INTHEPRESENCEOFK2CO3TOGIVEESTER164IN88YIELDFROM161LASTLY,THETRITYLGROUPWASREMOVEDWITH25AQUEOUSACETICACIDTOGIVEOLMESARTAN18IN81YIELDSYNTHETICAPPROACHESTOTHE2002NEWDRUGSMINIREVIEWSINMEDICINALCHEMISTRY,2004,VOL4,NO2225HOOOOOONOOOOHOOHTIPSOOOOOONOOOOTIPSOOHHOOOOOONOOOOTIPSOOHOOOOOONOOOOTIPSOOHSOONO2CLOOOOONOOOOHOOH322417817918021NO2SO2CLPTSA,MEOH/MECNRT,2H,88181DIPEA,DMAP,DCM,RT,18H781LICL,DMF,70OC5H,50248HF,2H,37182TIPSTRIFLATELUTIDINE,DCM0C,16H94OSCHEME21SYNTHESISOFPIMECROLIMUSPARECOXIBSODIUMDYNASTATPARECOXIBSODIUM19ISACYCLOOXYGENASE2COX2INHIBITORANDWASINTRODUCEDBYPHARMACIANOWPFIZERASANINJECTABLEFORMULATIONFORSHORTTERMTREATMENTOFPOSTOPERATIVEPAIN64PARECOXIBISAWATERSOLUBLEPRODRUGOFVALDECOXIB27THATUNDERGOESBIOTRANSFORMATIONINVIVOTORELEASEVALDECOXIB27THESYNTHESISSCHEME19OFPARECOXIBSODIUM19STARTEDFROMCOMMERCIALLYAVAILABLEDEOXYBENZOIN165DEOXYBENZOIN165WASTREATEDWITHHYDROXYLAMINEINETOH/H2O31TOGIVEDEOXYBENZOINOXIME166IN95YIELDDEPROTONATIONOFOXIME166WITHTWOEQUIVALENTSOFNHEXYLLITHIUMFOLLOWEDBYCONDENSATIONWITHETHYLACETATEAFFORDEDISOXAZOLINE167IN59YIELDTREATMENTOFISOXAZOLINE167WITHCHLORO